GlassScriptPhysician profile
Swetha Kadali
NPI 1902210875
$1,662.34
in general payments reported to CMS, 2019-2025
26 companies · $258 in 2025
The $258 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $72.55 · 2020: $75.00 · 2021: $168 · 2022: $246 · 2023: $618 · 2024: $226 · 2025: $258.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,101.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,101.37 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $271.14 | 2023-2025 | Ensite, Freestyle Libre 3, Proclaim |
| Amgen INC. | $170.00 | 2022-2025 | Evenity, Prolia |
| Novo Nordisk INC | $110.91 | 2021-2025 | Rybelsus, Ozempic |
| Esperion Therapeutics, INC. | $96.91 | 2020-2021 | |
| Abbvie INC. | $96.88 | 2021-2023 | |
| Pfizer INC. | $84.76 | 2021-2025 | |
| Medtronic, INC. | $82.38 | 2022-2024 | Intellis Adaptivestim, Venaseal, Minimed 770g |
| Gilead Sciences, INC. | $72.55 | 2019 | |
| Glaxosmithkline, LLC. | $72.39 | 2021-2025 | Shingrix |
| Bayer Healthcare Pharmaceuticals INC. | $70.11 | 2023-2025 | |
| Dexcom, INC. | $68.58 | 2023-2025 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $57.37 | 2022-2024 | Xifaxan, Cycloset |
| Janssen Pharmaceuticals, INC | $55.49 | 2022 | |
| Lilly USA, LLC | $53.84 | 2021-2024 | Zepbound, Mounjaro, Jardiance |
| Philips North America LLC | $49.58 | 2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $49.30 | 2023-2025 | Jardiance |
| Mannkind Corporation | $38.39 | 2022-2024 | |
| Cequr Corporation | $26.44 | 2022-2023 | Cequr Simplicity |
| Corcept Therapeutics | $23.30 | 2024 | Korlym |
| Sequel Med Tech, LLC | $20.42 | 2025 | Twiist |
| Recordati_rare_diseases_inc. | $18.82 | 2023 | Signifor Lar, Isturisa |
| Astrazeneca Pharmaceuticals LP | $16.36 | 2021 | |
| Acella Pharmaceuticals, LLC | $15.06 | 2023 | NP Thyroid 60 |
| Biohaven Pharmaceuticals, INC. | $14.13 | 2021 | |
| Xeris Pharmaceuticals, INC. | $13.97 | 2024 | Gvoke Hypopen |
| Currax Pharmaceuticals LLC | $13.26 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Swetha Kadali listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.